Treating MET Exon 14 NSCLC
The focus turns to therapeutic strategies for treating MET exon 14 non–small cell lung cancer.
Source: onclive.com
Page 50 - Nsclc News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Nsclc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Nsclc Today - Breaking & Trending Today
FDA Awards Orphan Drug Designation to Alisertib in ES-SCLC
The FDA has granted an orphan drug designation to alisertib (MLN8237) for the treatment of patients with extensive-stage small cell lung cancer.
Source: onclive.com
Defining Earlier Use of Immunotherapy in Patients With NSCLC
In the non–small cell lung cancer space, identifying the appropriate candidate to receive perioperative approaches, such as neoadjuvant or adjuvant therapy, remains the clinical objective.
Source: targetedonc.com
Dr Machtay on the Prognostic Value of Pre-Treatment Immunologic Biomarker Levels in NSCLC
Mitchell Machtay, MD, discusses the association between the levels of circulating immune biomarkers prior to immunotherapy and survival outcomes in patients with stage III non-small cell lung cancer.
Source: onclive.com
Dr Ricciuti on PD-L1 Expression and Long-Term Survival Outcomes With PD-L1 Inhibitors in Advanced NSCLC
Biagio Ricciuti, MD, discusses the association between PD-L1 expression levels and long-term survival with anti–PD-L1 monotherapy in patients with advanced non–small cell lung cancer.
Source: onclive.com